Evidence map›Paper›PMID 31882513›Full record

ArticleIn vivo (Athens, Greece)

E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.

Pinelopi Gkogkou, Evangelia Peponi, Dimitrios Ntaskagiannis, Samuel Murray, Asimo Demou, Ioannis Sainis, Elli Ioakeim, Evangelos Briasoulis, Pericles Tsekeris

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pinelopi GkogkouDepartment of Radiation Oncology, Norfolk and Norwich University Hospital, Norwich, U.K. pinelopi.gkogkou@nnuh.nhs.uk.
Evangelia PeponiDepartment of Radiation Oncology, University Hospital of Ioannina, Ioannina, Greece.
Dimitrios NtaskagiannisDepartment of Radiation Oncology, University Hospital of Ioannina, Ioannina, Greece.
Samuel MurrayGenekor SA, Athens, Greece.
Asimo DemouDepartment of Pathology,"Hatzikosta" Community Hospital, Ioannina, Greece.
Ioannis SainisInterscience Molecular Laboratory, Cancer Biobank Center, University of Ioannina, University Campus, Ioannina, Greece.
Elli IoakeimDepartment of Pathology,"Hatzikosta" Community Hospital, Ioannina, Greece.
Evangelos BriasoulisHematology Department and Interscience Molecular Laboratory, Cancer Biobank Center, University of Ioannina, Ioannina, Greece.
Pericles TsekerisDepartment of Radiation Oncology, University Hospital of Ioannina, Ioannina, Greece.
University Hospital of Ioannina · GRGeneral Hospital of Ioannina G. Hatzikosta · GRUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe aim of the study was to investigate whether E-cadherin and syndecan-1 are molecular markers of advanced non-small cell lung cancer (NSCLC). PATIENTS AND

methodsThe expression of E-cadherin and syndecan-1 (SDC1) was examined immunohistochemically on tissue specimens of 64 patients, with stage III disease at presentation. The obtained expression data were correlated with clinical parameters.

resultsNegative expression of SDC1 was correlated with squamous histology (p=0.002). E-cadherin positive expression was significantly associated with increased 2-year overall survival (OS) rate (p=0.032). In the multivariate Cox analysis, performance status 0-1 was an independent predictor of OS (p=0.001) and disease-free survival (DFS) (p=0.001). E-cadherin expression was an independent predictor of OS (p=0.007) and DFS (p=0.029).

conclusionE-cadherin might be a prognostic factor for OS and DFS in advanced stage NSCLC patients. Further investigations are needed for the establishment of E-cadherin and syndecan-1 as molecular markers, affecting treatment response and survival.

Indexed as

AdenocarcinomaAgedAged, 80 and overAntigens, CDBiomarkers, TumorCadherinsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapyFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMiddle AgedAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanSDC1 protein, humanSyndecan-1E-cadherinimmunohistochemistryNSCLCradiotherapysyndecan-1

Identifiers

PMID31882513
PMCPMC6984080
OpenAlexW2998455508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.